These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32175001)

  • 1. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
    Lin HY; Han HW; Wang YS; He DL; Sun WX; Feng L; Wen ZL; Yang MK; Lu GH; Wang XM; Qi JL; Yang YH
    Chin Med; 2020; 15():23. PubMed ID: 32175001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
    Wolfson B; Padget MR; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER-mediated anti-tumor effects of shikonin on breast cancer.
    Yang Y; Gao W; Tao S; Wang Y; Niu J; Zhao P; Rao C; Yang L
    Eur J Pharmacol; 2019 Nov; 863():172667. PubMed ID: 31545985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
    Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
    Tang B; Peng ZH; Jiang J
    Zhonghua Wai Ke Za Zhi; 2005 Dec; 43(23):1545-9. PubMed ID: 16412295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells.
    Kim KH; Kim JY; Kwak JH; Pyo S
    Phytomedicine; 2015 Aug; 22(9):820-8. PubMed ID: 26220629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
    Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
    Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
    Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
    Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
    Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
    Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
    Lv F; Yu Y; Zhang B; Liang D; Li ZM; You W
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):870-876. PubMed ID: 24337851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.